Tag:
ThromboGenics
Latest Headlines
Latest Headlines
Novartis grabs rights to eye drug in $494M deal
Belgian biotech ThromboGenics ( $ THR ) has picked up a major partnership with the Alcon unit of Swiss drug giant Novartis ( $NVS ) for its experimental therapeutic for an eye ailment known as symptomatic vitreomacular adhesion, or VMA. And the deal with Alcon, which grants rights to market the eye drug outside the U.S., could be worth up to €375 million ($494 million) to ThromboGenics.
ThromboGenics gears up marketing plans for eyeball injection drug
Belgium's ThromboGenics is trying to make its likely New Year's wish a reality: A 2012 commercial launch of ocriplasmin to treat symptomatic vitreomacular adhesion by way of an injection into the
ThromboGenics prepares for future FDA approval filing
As Belgian biotech ThromboGenics sets its sights on approval for its eye disorder treatment ocriplasmin, the company isn't worrying about its cash flow. According to a statement, it is prepared for
ThromboGenics names new CEO
ThromboGenics' current COO Patrik De Haes has been appointed to succeed Professor Désiré Collen as the company's new CEO. No specific reasons were given for the change, but Collen--who
Positive data paves way for ThromboGenics trial
ThromboGenics is touting data from a Phase IIb trial of microplasmin for vitreous injection, saying it resolved the underlying disease in close to a third of all patients in one dosage group without
Roche signs up for $774M development pact
Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront
